US Food and Drug Administration Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process - Nasdaq

US Food and Drug Administration Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process  Nasdaq

Expands Patient Access to Andexxa, the First and Only Antidote for Reversal of the Factor Xa Inhibitors Rivaroxaban or Apixaban–. –Full Commercial.